Malaysia Device, Drug Markets To Grow Despite Economic Crisis
This article was originally published in PharmAsia News
The demand for medical devices and pharmaceuticals is expected to remain strong enough for the health care industry in Malaysia to weather the global financial crisis, insiders say. The country expects to count 1 million patients this year, up from 850,000 last year, indicating a recession-proof industry, according to a professor. A supplier of medical products agreed the demand would remain strong, allowing the industry to continue investing in technology and innovations. In general, however, spending decisions are expected to be more cautious because of the financial climate. (Click here for more
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.